nach oben

Erschienen in:

19.10.2019 | Original Paper

A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis

verfasst von: Michael M. Kreusser, Martin J. Volz, Benjamin Knop, Philipp Ehlermann, Bastian Schmack, Arjang Ruhparwar, Ute Hegenbart, Stefan O. Schönland, Hugo A. Katus, Philip W. Raake

Erschienen in: Clinical Research in Cardiology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Cardiac amyloidosis, caused by deposition of immunoglobulin light chains (AL) or transthyretin (ATTR), carries a poor prognosis. Established risk scores for amyloidosis may not predict outcomes in those patients who develop advanced heart failure and who are potential candidates for heart transplantation. Here, we aimed to identify predictive parameters for patients with severe heart failure due to amyloidosis.

Methods

Out of > 1000 patients with cardiac amyloidosis (AL or ATTR) admitted to our centre between September 1998 and January 2016, a cohort of 120 patients with a complete cardiac assessment at diagnosis, including right heart catheterization, echocardiography and biomarkers, was analysed retrospectively in this study. Primary endpoint was all-cause mortality. We performed univariate and multivariate Cox regression analysis, generated risk scores to predict outcomes in AL and ATTR amyloidosis and compared those to established risk models for amyloidosis.

Results

In the Cox multivariate model, high-sensitivity troponin T (hsTnT; hazard ratio (HR) 1.003; confidence interval (CI) 1.001–1.005; p = 0.009) and mean pulmonary artery pressure (HR 1.061; CI 1.024–1.100; p = 0.001) were found to significantly and independently predict outcomes for AL amyloidosis, whereas QRS duration (HR 1.021; CI 1.004–1.039; p = 0.013), hsTnT (HR 1.021; CI 1.006–1.036; p = 0.006) and N-terminal pro-brain natriuretic peptide (HR 1.0003; CI 1.0001–1.0004; p = 0.002) were the best predictors for ATTR amyloidosis. A simple risk score (“HeiRisk”) including these parameters for AL and ATTR allowed a more precise risk stratification in our patient population compared to established risk models.

Conclusions

Risk stratification for cardiac amyloidosis with the newly developed “HeiRisk” score may be superior to other staging systems for patients with advanced heart failure due to amyloid cardiomyopathy.

Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387(10038):2641–2654. https://doi.org/10.1016/S0140-6736(15)01274-X CrossRefPubMed

Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112(13):2047–2060. https://doi.org/10.1161/CIRCULATIONAHA.104.489187 CrossRefPubMed

Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 68(12):1323–1341. https://doi.org/10.1016/j.jacc.2016.06.053 CrossRefPubMed

Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66(21):2451–2466. https://doi.org/10.1016/j.jacc.2015.09.075 CrossRefPubMed

Aus dem Siepen F, Hein S, Prestel S, Baumgartner C, Schonland S, Hegenbart U, Rocken C, Katus HA, Kristen AV (2019) Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01467-1 CrossRefPubMed

Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164(2):222–228e221. https://doi.org/10.1016/j.ahj.2012.04.015 CrossRefPubMed

Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121(17):3420–3427. https://doi.org/10.1182/blood-2012-12-473066 CrossRefPubMed

Escher F, Senoner M, Doerler J, Zaruba MM, Messner M, Mussner-Seeber C, Ebert M, Ensinger C, Mair A, Kroiss A, Ulmer H, Schneiderbauer-Porod S, Ebner C, Poelzl G (2019) When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01490-2 CrossRefPubMedPubMedCentral

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007–1016. https://doi.org/10.1056/NEJMoa1805689 CrossRefPubMed

10.

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21. https://doi.org/10.1056/NEJMoa1716153 CrossRefPubMed

11.

Gertz MA (2018) Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol 93(9):1169–1180. https://doi.org/10.1002/ajh.25149 CrossRefPubMed

12.

Kristen AV, Kreusser MM, Blum P, Schonland SO, Frankenstein L, Dosch AO, Knop B, Helmschrott M, Schmack B, Ruhparwar A, Hegenbart U, Katus HA, Raake PWJ (2018) Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant 37(5):611–618. https://doi.org/10.1016/j.healun.2017.11.015 CrossRefPubMed

13.

Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M (2017) Heart transplantation in cardiac amyloidosis. Heart Fail Rev 22(3):317–327. https://doi.org/10.1007/s10741-017-9601-z CrossRefPubMed

14.

Davis MK, Lee PH, Witteles RM (2015) Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 34(5):658–666. https://doi.org/10.1016/j.healun.2014.09.006 CrossRefPubMed

15.

Gray Gilstrap L, Niehaus E, Malhotra R, Ton VK, Watts J, Seldin DC, Madsen JC, Semigran MJ (2014) Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant 33(2):149–156. https://doi.org/10.1016/j.healun.2013.09.004 CrossRefPubMed

16.

Hsich EM, Rogers JG, McNamara DM, Taylor DO, Starling RC, Blackstone EH, Schold JD (2016) Does survival on the heart transplant waiting list depend on the underlying heart disease? JACC Heart Fail 4(9):689–697. https://doi.org/10.1016/j.jchf.2016.03.010 CrossRefPubMedPubMedCentral

17.

Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22(18):3751–3757. https://doi.org/10.1200/JCO.2004.03.029 CrossRefPubMed

18.

Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799–2806. https://doi.org/10.1093/eurheartj/ehx589 CrossRefPubMed

19.

World Medical A (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194. https://doi.org/10.1001/jama.2013.281053 CrossRef

20.

Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79(4):319–328. https://doi.org/10.1002/ajh.20381 CrossRefPubMed

21.

Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51(10):1022–1030. https://doi.org/10.1016/j.jacc.2007.10.049 CrossRefPubMed

22.

Kreusser MM, Geis NA, Berlin N, Greiner S, Pleger ST, Bekeredjian R, Katus HA, Raake PW (2019) Invasive hemodynamics and cardiac biomarkers to predict outcomes after percutaneous edge-to-edge mitral valve repair in patients with severe heart failure. Clin Res Cardiol 108(4):375–387. https://doi.org/10.1007/s00392-018-1365-5 CrossRefPubMed

23.

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–995. https://doi.org/10.1200/JCO.2011.38.5724 CrossRefPubMedPubMedCentral

24.

Koch A, Tochtermann U, Remppis A, Dengler TJ, Schnabel PA, Hagl S, Sack FU (2006) The Eurotransplant High-Urgency Heart Transplantation Program: an option for patients in acute heart failure? Thorac Cardiovasc Surg 54(6):414–417. https://doi.org/10.1055/s-2006-924245 CrossRefPubMed

25.

d’Humieres T, Fard D, Damy T, Roubille F, Galat A, Doan HL, Oliver L, Dubois-Rande JL, Squara P, Lim P, Ternacle J (2018) Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. Arch Cardiovasc Dis 111(10):582–590. https://doi.org/10.1016/j.acvd.2018.03.004 CrossRefPubMed

26.

Sugiura A, Kitahara H, Iwahana T, Suzuki N, Okada S, Miyauchi H, Kobayashi Y, Werner N (2019) Association of heart failure duration with clinical prognosis in advanced heart failure. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01515-w CrossRefPubMed

27.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077 CrossRefPubMed

28.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975. https://doi.org/10.1002/ejhf.592 CrossRefPubMed

29.

Stienen S, Rossignol P, Barros A, Girerd N, Pitt B, Zannad F, Ferreira JP (2019) Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01500-3 CrossRefPubMed

30.

Ferreira JP, Duarte K, Montalescot G, Pitt B, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Rossignol P, Vincent J, Zannad F (2018) Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clin Res Cardiol 107(1):49–59. https://doi.org/10.1007/s00392-017-1157-3 CrossRefPubMed

31.

Legrand M, Ludes PO, Massy Z, Rossignol P, Parenica J, Park JJ, Ishihara S, AlHabib KF, Maggioni A, Miro O, Sato N, Cohen-Solal A, Fairman E, Lassus J, Harjola VP, Mueller C, Peacock FW, Choi DJ, Plaisance P, Spinar J, Kosiborod M, Mebazaa A, Gayat E, Network G, network I-C (2018) Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clin Res Cardiol 107(3):214–221. https://doi.org/10.1007/s00392-017-1173-3 CrossRefPubMed

32.

Jobs A, Abdin A, de Waha-Thiele S, Eitel I, Thiele H, de Wit C, Vonthein R (2019) Angiotensin-converting-enzyme inhibitors in hemodynamic congestion: a meta-analysis of early studies. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01456-4 CrossRefPubMed

33.

Kreusser MM, Geis NA, Berlin N, Greiner S, Pleger ST, Bekeredjian R, Katus HA, Raake PW (2018) Invasive hemodynamics and cardiac biomarkers to predict outcomes after percutaneous edge-to-edge mitral valve repair in patients with severe heart failure. Clin Res Cardiol. https://doi.org/10.1007/s00392-018-1365-5 CrossRefPubMed

34.

Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, Investigators C (2018) Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. https://doi.org/10.1056/NEJMoa1806640 CrossRefPubMedPubMedCentral

35.

Jilek C, Lewalter T, Pauschinger M, von Scheidt W, Frankenstein L, Pfister O, Hambrecht R, Bruder O, Brachmann J, Hartmann A, Strasser R, Hochadel M, Senges J (2019) Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01503-0 CrossRefPubMed

36.

Schiedat F, Schone D, Aweimer A, Bosche L, Ewers A, Gotzmann M, Patsalis PC, Mugge A, Kloppe A (2019) Multipoint left ventricular pacing with large anatomical separation improves reverse remodeling and response to cardiac resynchronization therapy in responders and non-responders to conventional biventricular pacing. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01499-7 CrossRefPubMed

37.

Pastori D, Miyazawa K, Li Y, Szekely O, Shahid F, Farcomeni A, Lip GYH (2019) Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01493-z CrossRefPubMedPubMedCentral

38.

Geller JC, Lewalter T, Bruun NE, Taborsky M, Bode F, Nielsen JC, Stellbrink C, Schon S, Muhling H, Oswald H, Reif S, Kaab S, Illes P, Proff J, Dagres N, Hindricks G, IN-TIME Study Group (2019) Implant-based multi-parameter telemonitoring of patients with heart failure and a defibrillator with vs. without cardiac resynchronization therapy option: a subanalysis of the IN-TIME trial. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01447-5 CrossRefPubMedPubMedCentral

39.

Baumann S, Werner N, Ibrahim K, Westenfeld R, Al-Rashid F, Sinning JM, Westermann D, Schafer A, Karatolios K, Bauer T, Becher T, Akin I (2018) Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella(R) pump: results from the German Impella(R) registry. Clin Res Cardiol 107(8):653–657. https://doi.org/10.1007/s00392-018-1230-6 CrossRefPubMed

40.

Kreusser MM, Tschierschke R, Beckendorf J, Baxmann T, Frankenstein L, Dosch AO, Schultz JH, Giannitsis E, Pleger ST, Ruhparwar A, Karck M, Katus HA, Raake PW (2018) The need for dedicated advanced heart failure units to optimize heart failure care: impact of optimized advanced heart failure unit care on heart transplant outcome in high-risk patients. ESC Heart Fail. https://doi.org/10.1002/ehf2.12314 CrossRefPubMedPubMedCentral

41.

Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Winkler S, Vettorazzi E, Polze A, Stangl K, Hartmann O, Marx A, Neuhaus P, Scherf M, Kirwan BA, Anker SD (2018) Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. Eur J Heart Fail 20(10):1485–1493. https://doi.org/10.1002/ejhf.1300 CrossRefPubMed

42.

Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, Abraham WT, Investigators CT (2017) Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 70(15):1875–1886. https://doi.org/10.1016/j.jacc.2017.08.010 CrossRefPubMed

43.

Luedde M, Spehlmann ME, Frey N (2018) Progress in heart failure treatment in Germany. Clin Res Cardiol 107(Suppl 2):105–113. https://doi.org/10.1007/s00392-018-1317-0 CrossRefPubMed

44.

Mehra MR, Goldstein DJ, Uriel N, Cleveland JC Jr, Yuzefpolskaya M, Salerno C, Walsh MN, Milano CA, Patel CB, Ewald GA, Itoh A, Dean D, Krishnamoorthy A, Cotts WG, Tatooles AJ, Jorde UP, Bruckner BA, Estep JD, Jeevanandam V, Sayer G, Horstmanshof D, Long JW, Gulati S, Skipper ER, O’Connell JB, Heatley G, Sood P, Naka Y, MOMENTUM 3 Investigators (2018) Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med 378(15):1386–1395. https://doi.org/10.1056/NEJMoa1800866 CrossRefPubMed

45.

Schmitto JD, Zimpfer D, Fiane AE, Larbalestier R, Tsui S, Jansz P, Simon A, Schueler S, Strueber M (2016) Long-term support of patients receiving a left ventricular assist device for advanced heart failure: a follow-up analysis of the Registry to Evaluate the HeartWare Left Ventricular Assist System. Eur J Cardiothorac Surg 50(5):834–838. https://doi.org/10.1093/ejcts/ezw224 CrossRefPubMed

46.

Hamed S, Schmack B, Mueller F, Ehlermann P, Hittmann D, Ruhparwar A, Katus HA, Raake PW, Kreusser MM (2019) Implementation of an intensified outpatient follow-up protocol improves outcomes in patients with ventricular assist devices. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01451-9 CrossRefPubMed

47.

Doenst T, Bargenda S, Kirov H, Moschovas A, Tkebuchava S, Safarov R, Diab M, Faerber G (2019) Cardiac surgery 2018 reviewed. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01470-6 CrossRefPubMed

48.

Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV (2017) Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid 24(sup1):132–133. https://doi.org/10.1080/13506129.2016.1272453 CrossRefPubMed

49.

Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA (2013) Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant 32(5):563–568. https://doi.org/10.1016/j.healun.2013.01.987 CrossRefPubMed

50.

Scully MS, Wessman DE, McKee JM, Francisco GM, Nayak KR, Kobashigawa JA (2017) Total artificial heart implantation as a bridge to heart transplantation in an active duty service member with amyloid cardiomyopathy. Mil Med 182(3):e1858–e1860. https://doi.org/10.7205/MILMED-D-16-00122 CrossRefPubMed

51.

Grupper A, Park SJ, Pereira NL, Schettle SD, Gerber Y, Topilsky Y, Edwards BS, Daly RC, Stulak JM, Joyce LD, Kushwaha SS (2015) Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant 34(8):1042–1049. https://doi.org/10.1016/j.healun.2015.03.012 CrossRefPubMed

52.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 118(4):865–873. https://doi.org/10.1182/blood-2011-02-334227 CrossRefPubMed

53.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schonland SO (2017) Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica 102(8):1424–1431. https://doi.org/10.3324/haematol.2016.163246 CrossRefPubMedPubMedCentral

54.

Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ (2012) Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 119(23):5397–5404. https://doi.org/10.1182/blood-2012-02-413161 CrossRefPubMedPubMedCentral

55.

Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N, Gastineau DA (2007) Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 92(10):1415–1418CrossRefPubMed

56.

Kristen AV, Sack FU, Schonland SO, Hegenbart U, Helmke BM, Koch A, Schnabel PA, Rocken C, Hardt S, Remppis A, Goldschmidt H, Karck M, Ho AD, Katus HA, Dengler TJ (2009) Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail 11(10):1014–1020. https://doi.org/10.1093/eurjhf/hfp121 CrossRefPubMed

57.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M (2001) An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28(7):637–642. https://doi.org/10.1038/sj.bmt.1703200 CrossRefPubMed

58.

Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators (2017) Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail. https://doi.org/10.1161/circheartfailure.116.003815 CrossRefPubMed

59.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31. https://doi.org/10.1056/NEJMoa1716793 CrossRefPubMed

60.

Sultan MB, Gundapaneni B, Schumacher J, Schwartz JH (2017) Treatment with tafamidis slows disease progression in early-stage transthyretin cardiomyopathy. Clin Med Insights Cardiol 11:1179546817730322. https://doi.org/10.1177/1179546817730322 CrossRefPubMedPubMedCentral

61.

Grogan M, Gertz M, McCurdy A, Roeker L, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A (2016) Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience. World J Transplant 6(2):380–388. https://doi.org/10.5500/wjt.v6.i2.380 CrossRefPubMedPubMedCentral

62.

Heim C, Nooh E, Kondruweit M, Weyand M, Tandler R (2013) Single centre experience with prolonged waiting time on transplant list with “high-urgency” status. Thorac Cardiovasc Surg 61(3):251–254. https://doi.org/10.1055/s-0032-1322624 CrossRefPubMed

63.

Bodez D, Ternacle J, Guellich A, Galat A, Lim P, Radu C, Guendouz S, Bergoend E, Couetil JP, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Deux JF, Mohty D, Damy T (2016) Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid 23(3):158–167. https://doi.org/10.1080/13506129.2016.1194264 CrossRefPubMed

64.

Katus HA, Giannitsis E (2018) Biomarker in cardiology: DGK welcomes ESC Munich 2018. Clin Res Cardiol 107(Suppl 2):10–15. https://doi.org/10.1007/s00392-018-1300-9 CrossRefPubMed

65.

Ferreira JP, Pizard A, Machu JL, Bresso E, Rocca HB, Girerd N, Leroy C, Gonzalez A, Diez J, Heymans S, Devignes MD, Rossignol P, Zannad F, FIBRO-TARGETS Investigators (2019) Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case–control analyses. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01480-4 CrossRefPubMed

66.

Schumacher K, Dagres N, Hindricks G, Husser D, Bollmann A, Kornej J (2017) Characteristics of PR interval as predictor for atrial fibrillation: association with biomarkers and outcomes. Clin Res Cardiol 106(10):767–775. https://doi.org/10.1007/s00392-017-1109-y CrossRefPubMed

67.

Frea S, Pidello S, Volpe A, Canavosio FG, Galluzzo A, Bovolo V, Camarda A, Golzio PG, D’Ascenzo F, Bergerone S, Rinaldi M, Gaita F (2019) Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01521-y CrossRefPubMed

68.

Chen X, Savarese G, Dahlstrom U, Lund LH, Fu M (2019) Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01477-z CrossRefPubMed

69.

Tager T, Wiebalck C, Frohlich H, Corletto A, Katus HA, Frankenstein L (2017) Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure. Clin Res Cardiol 106(12):974–985. https://doi.org/10.1007/s00392-017-1147-5 CrossRefPubMed

70.

Park JJ, Park CS, Mebazaa A, Oh IY, Park HA, Cho HJ, Lee HY, Kim KH, Yoo BS, Kang SM, Baek SH, Jeon ES, Kim JJ, Cho MC, Chae SC, Oh BH, Choi DJ (2019) Characteristics and outcomes of HFpEF with declining ejection fraction. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01505-y CrossRefPubMedPubMedCentral

71.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA (2019) The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clin Res Cardiol. https://doi.org/10.1007/s00392-019-01513-y CrossRefPubMedPubMedCentral

72.

Siepen FAD, Bauer R, Voss A, Hein S, Aurich M, Riffel J, Mereles D, Rocken C, Buss SJ, Katus HA, Kristen AV (2018) Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol 107(2):158–169. https://doi.org/10.1007/s00392-017-1167-1 CrossRefPubMed

73.

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R (2014) Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med 6(11):1493–1507. https://doi.org/10.15252/emmm.201404190 CrossRefPubMedPubMedCentral

74.

Hu K, Liu D, Nordbeck P, Cikes M, Stork S, Kramer B, Gaudron PD, Schneider A, Knop S, Ertl G, Bijnens B, Weidemann F, Herrmann S (2015) Impact of monitoring longitudinal systolic strain changes during serial echocardiography on outcome in patients with AL amyloidosis. Int J Cardiovasc Imaging 31(7):1401–1412. https://doi.org/10.1007/s10554-015-0711-1 CrossRefPubMed

75.

Nakahashi T, Arita T, Yamaji K, Inoue K, Yokota T, Hoshii Y, Fukunaga M, Nomura A, Watanabe H, Miura S, Isotani A, Soga Y, Ando K, Iwabuchi M, Yokoi H, Nosaka H, Yamagishi M, Nobuyoshi M (2014) Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy. Int J Cardiol 176(3):753–759. https://doi.org/10.1016/j.ijcard.2014.07.100 CrossRefPubMed

Titel: A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis
verfasst von: Michael M. Kreusser
Martin J. Volz
Benjamin Knop
Philipp Ehlermann
Bastian Schmack
Arjang Ruhparwar
Ute Hegenbart
Stefan O. Schönland
Hugo A. Katus
Philip W. Raake
Publikationsdatum: 19.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 6/2020
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-019-01559-y

Neu im Fachgebiet Kardiologie

23.04.2024 | Ablationstherapie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Outcome differences and device performance of the subcutaneous ICD in patients with and without structural heart disease

Transcatheter versus surgical aortic valve replacement in low-risk patients: a meta-analysis of randomized trials

Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study

Determinants of sinus rhythm maintenance in patients with early-persistent atrial fibrillation and heart failure

Time-updated resting heart rate predicts mortality in patients with COPD

Performance of the entirely subcutaneous ICD in borderline indications

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie